To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse

Condition(s) studied

Investigational drug(s) / intervention(s)

Diagnosis and Physical Examination of Psoriasis: This study divided patients with plaque psoriasis treated with biological agents into a recurrent group and a non recurrent group based on whether they recurred or not

Study summary

In recent years, an increasing number of patients who have experienced poor efficacy or adverse drug reactions using traditional treatment regimens have received biologic therapy and achieved satisfactory treatment results. However, we also found that some patients have poor reactions to biological agents. Biological agents are often the final treatment choice for most patients, and patients often have high expectations for this treatment plan. Therefore, exploring the factors that affect the efficacy of biological agents and effective follow-up treatment plans when there is poor response to biological agents is of great significance for the treatment of psoriasis patients.

The main research objective of this project is to observe and record the clinical characteristics and efficacy of plaque psoriasis patients treated with biological agents in the real world. 2. Explore the influencing factors of recurrence in plaque psoriasis patients receiving biological therapy in the real world, in order to increase awareness and awareness of this phenomenon, and provide guidance for preventing recurrence after biological therapy. 3. Record the follow-up treatment plans or response measures for recurrent patients, and compare the efficacy of different treatment plans.

This study is a case-control study that recruited patients with plaque psoriasis who have received biological therapy for more than half a year. A questionnaire survey was conducted to understand their general information, disease-related clinical data, and laboratory examination data. Univariate analysis was used to compare all variables between groups, and logistic regression analysis was performed on variables with statistical differences. Corresponding ROC curves were then drawn. Perform a separate analysis of the Adalimumab group according to the above steps. In addition, descriptive analysis was conducted on the characteristics that may be related to the disease in the recurrence group, and the efficacy of different treatment plans after recurrence was compared.

Eligibility

Primary outcome measure(s)

• General Information — 12/1/2022-12/1/2024
  Age, gender, occupation, education, height, weight, abdominal circumference, history of smoking or excessive drinking, dietary preferences, sleep quality, exercise status
• Psoriasis related information — 12/1/2022-12/1/2024
  The duration of illness, the name and administration scheme of the biological agent, the age when using the biological agent, the age of the first onset of psoriasis, the body surface involved area (BSA) of the skin lesions when injecting the first dose of biological agent, whether to comply with medical advice, whether to have psoriasis comorbidity, whether to treat other diseases at the same time, whether to have a family history of psoriasis, whether to involve joints, whether to involve special parts, whether to have infectious diseases during the treatment period, whether to vaccinate COVID-19 vaccine

Trial sites (1)

More First Affiliated Hospital Xi'an Jiaotong University trials in China

Other trials for the same condition